Study to Assess VB-201 in Patients With Psoriasis

Exclusion Criteria

• •The subject presents with the predominant type of psoriasis as guttate, erythrodermic, inverse, pustular or palmo-plantar or an unstable form of psoriasis
• •The subject has not undergone wash-out periods of sufficient duration for the following treatments at Baseline: Topical psoriasis treatments; Systemic, oral or injected, psoriasis treatments; Phototherapy
• •The subject anticipates getting enough ultra-violet light during the study to cause psoriasis to improve
• •The subject has a known allergy or sensitivity to the study treatment(s) or to any of the excipients contained in the study drug formulation
• •History of cancer, the exception is skin cancer
• •Has a clinically significant systemic infection within 30 days of Day 0, or a history or presence of recurrent or chronic infection
• •Evidence of tuberculosis as indicated by a positive tuberculin skin test or a quantiferon test in subjects known to have a + PPD and a negative chest x-ray at screening
• •History of clinically significant hypoglycemia
• •Subjects with currently active peptic ulcer / gastroesophageal reflux disease